Posting this under the heading it deserves: Tesamorelin has an approved indication — what that changes about the evidence Everything below is what sits behind that.
What changes if the standard account of Tesamorelin is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.
Working through the consequences rather than the evidence, since others here are better placed on the evidence.
Sensible. I would want the same detail before I acted on it either.
Confirming post #4 from a second method, which matters more than confirming it from a second person.
The arithmetic on Tesamorelin is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.
I had written a reply contradicting post #2 and deleted it. Here is what survived.
The most useful single question to ask about any compound in this family is what the published human evidence actually consists of. In several cases the honest answer is a handful of small studies.
This has been discussed before and I could not find the thread, so, again.
Worth stating the null on Tesamorelin before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.
My position on Tesamorelin is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large randomised controlled trials are rare. Most evidence is mechanistic or from small studies. This is why this subcategory has higher sourcing standards than most.
A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.
It reads as pedantry until the day it does not.
I had written a reply contradicting post #10 and deleted it. Here is what survived.
Tesamorelin has an approved indication in HIV-associated lipodystrophy. That is the only compound in this class with a registration-quality evidence base from a proper trial programme. Generalising from that narrow population to healthy adults is a substantial extrapolation.
Research-use-only secretagogues are not approved for human use. That statement is doing real work in this subcategory, where the published evidence base is thinner than the volume of confident discussion.
I would put moderate confidence on the mainstream reading of Tesamorelin and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
Picking up post #13: that is the part I would want checked first.
The question underneath Tesamorelin is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.
Coming back to post #13, because the follow-up matters more than the original answer.
Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach.
I have left out the parts I could not verify.
Post #13 is right about the mechanism and I think understates the practical bit.
Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism is plausible. They cannot show magnitude of effect in humans or safety profile in humans. That gap is larger for secretagogues than for incretin agonists because the human evidence is thinner.
What a well-designed human trial of a secretagogue would look like: randomised, placebo-controlled, adequate sample size, IGF-1 as primary outcome, muscle and strength as secondary outcomes, adequate follow-up duration. Very few secretagogue trials meet that description.
Posting it because the silence on this was starting to look like agreement.
I will take the caveat as seriously as the claim, which is the point of putting it there.
Reading back through the Tesamorelin threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
Building on post #17 rather than restating it.
What I would want before treating Tesamorelin as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing.
Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.
Where I part company with post #20, and it is a narrow parting.
The reason Tesamorelin keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.
Adding the measurement that post #22 says would settle it.
Why this subcategory is stricter about sourcing than most: the evidence base is weaker and that is precisely why documentation quality matters more. A supplier page that clearly identifies the compound and the purity is more valuable for secretagogues than for incretin agonists where the evidence base is stronger.
Reporting the observation and leaving the explanation open deliberately.
Marking my uncertainty on Tesamorelin explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.
If someone has run Tesamorelin properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
Tesamorelin is the compound in this family with the strongest regulatory evidence base, and it was studied in a specific population for a specific indication. That evidence does not generalise to the way it is usually discussed.
That is a fair summary of where the discussion has got to.
Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism is plausible. They cannot show magnitude of effect in humans or safety profile in humans. That gap is larger for secretagogues than for incretin agonists because the human evidence is thinner.
Speaking for myself and not for anyone else who has posted here.